PMID- 26937232
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160303
LR  - 20200929
IS  - 1598-2629 (Print)
IS  - 2092-6685 (Electronic)
IS  - 1598-2629 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Feb
TI  - Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications.
PG  - 52-60
LID - 10.4110/in.2016.16.1.52 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that 
      bridge innate and adaptive immune responses, thereby leading to immune 
      activation. DCs have been known to recognize pathogen-associated molecular 
      patterns such as lipopolysaccharides (LPS) and nucleic acids via their pattern 
      recognition receptors, which trigger signaling of their maturation and effector 
      functions. Furthermore, DCs take up and process antigens as a form of peptide 
      loaded on the major histocompatibility complex (MHC) and present them to T cells, 
      which are responsible for the adaptive immune response. Conversely, DCs can also 
      play a role in inducing immune suppression under specific circumstances. From 
      this perspective, the role of DCs is related to tolerance rather than immunity. 
      Immunologists refer to these special DCs as tolerogenic DCs (tolDCs). However, 
      the definition of tolDCs is controversial, and there is limited information on 
      their development and characteristics. In this review, we discuss the current 
      concept of tolDCs, cutting-edge methods for generating tolDCs in vitro, and 
      future applications of tolDCs, including clinical use.
FAU - Yoo, Seungbo
AU  - Yoo S
AD  - System Immunology Laboratory, Department of Biochemistry, College of Life Science 
      & Biotechnology, Yonsei University, Seoul 03722, Korea.
FAU - Ha, Sang-Jun
AU  - Ha SJ
AD  - System Immunology Laboratory, Department of Biochemistry, College of Life Science 
      & Biotechnology, Yonsei University, Seoul 03722, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160225
PL  - Korea (South)
TA  - Immune Netw
JT  - Immune network
JID - 101137270
PMC - PMC4770100
OTO - NOTNLM
OT  - Clinical use
OT  - In vitro generation
OT  - Tolerogenic dendritic cell
COIS- CONFLICTS OF INTEREST: The authors have no financial conflict of interest.
EDAT- 2016/03/05 06:00
MHDA- 2016/03/05 06:01
PMCR- 2016/02/01
CRDT- 2016/03/04 06:00
PHST- 2015/12/22 00:00 [received]
PHST- 2016/02/05 00:00 [revised]
PHST- 2016/02/07 00:00 [accepted]
PHST- 2016/03/04 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2016/03/05 06:01 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.4110/in.2016.16.1.52 [doi]
PST - ppublish
SO  - Immune Netw. 2016 Feb;16(1):52-60. doi: 10.4110/in.2016.16.1.52. Epub 2016 Feb 
      25.